Sigilon Therapeutics
Sigilon Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0001558370-21-006673
- Document
- 8-K
- Exhibit 99.1
- Press release
- Reports quarterly results (2.02)
- Makes a Regulation FD disclosure (7.01)
Not explained yet; the original is on EDGAR.
Similar companies
Same SIC code (2834) and public float not reported.
